The poly ADP ribose polymerase (PARP) inhibitor olaparib has been approved for the treatment of four different tumor types in the presence of BRCA1 or BRCA2 mutations3–6, the PD-1 inhibitor pembrolizumab has been approved for the treatment of solid tumors with microsatellite instabilities or mismatch repair deficiencies7 and high TMB8, and the antibody-drug conjugate trastuzumab deruxtecan has shown clinical efficacy in a variety of HER2-positive solid tumors9–11. This evidence concerns the gene BRCA2 and neoplasm.